Actively Recruiting

Age: 18Years +
All Genders
NCT07161583

Advanta VXT and Flixene PMCF Registry

Led by Atrium Medical Corporation · Updated on 2026-03-13

1000

Participants Needed

2

Research Sites

53 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the registry is to evaluate the long-term safety and performance of Advanta VXT and Flixene vascular grafts for repair or replacement of peripheral arteries. This registry is also intended to provide further data on the clinical usefulness of the Advanta VXT and Flixene vascular grafts.

CONDITIONS

Official Title

Advanta VXT and Flixene PMCF Registry

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing and able to provide legally effective written informed consent as required by IRB/EC
  • Male and female patients who have undergone replacement or repair of peripheral arteries using the Advanta VXT or Flixene vascular graft
  • At least 18 years old at the time of the procedure
  • Available medical records with a minimum of 36 months of follow-up data
Not Eligible

You will not qualify if you...

  • Active infection in the region of graft placement at the time of implantation of the Advanta VXT or Flixene vascular graft

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

2

CHU de Brest

Brest, Brittany Region, France

Actively Recruiting

Loading map...

Research Team

S

Senior Manager, Clinical Affairs

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here